Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HBP.TO
- Price
- 0.78
- Stock movement up
- +- (%)
- Company name
- Helix BioPharma Corp.
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 38.24M
- Ent value
- 38.73M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -9.26%
- 1 year return
- -13.33%
- 3 year return
- -10.83%
- 5 year return
- -36.58%
- 10 year return
- -22.12%
Last updated: 2025-04-18
DIVIDENDS
HBP.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.02M |
| EPS (TTM) | -0.19 |
| FCF per share (TTM) | -0.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -13.00K |
| Operating income (TTM) | -9.25M |
| Net income (TTM) | -9.27M |
| EPS (TTM) | -0.19 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.08M |
| Net receivables | 54.00K |
| Total current assets | 1.46M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.84M |
| Total assets | 1.49M |
| Accounts payable | 855.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.58M |
| Total liabilities | 1.58M |
| Shareholder's equity | -90.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.22M |
| Capital expenditures (TTM) | 14.00K |
| Free cash flow (TTM) | -5.23M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -622.23% |
| Return on Invested Capital | 10294.44% |
| Cash Return on Invested Capital | 5814.44% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.78 |
| Daily high | 0.78 |
| Daily low | 0.78 |
| Daily Volume | 0K |
| All-time high | 40.00 |
| 1y analyst estimate | 2.50 |
| Beta | -0.84 |
| EPS (TTM) | -0.19 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| HBP.TO | S&P500 | |
| Current price drop from All-time high | -98.05% | -14.12% |
| Highest price drop | -98.58% | -56.47% |
| Date of highest drop | 6 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -74.10% | -11.07% |
| Avg time to new high | 236 days | 12 days |
| Max time to new high | 6200 days | 1805 days |
COMPANY DETAILS
Marketcap
38.24M
Marketcap category
Small-cap
Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Employees
7
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We can readily understand why investors are attracted to unprofitable companies. For example, although...
March 16, 2025
TORONTO (AP) — Helix Biopharma Corp. HBPCF) on Thursday reported a loss of $3.9 million in its fiscal fourth quarter. The Toronto-based company said it had a loss of 8 cents per share.
October 25, 2024